Stage 3 lung cancer: what changes when surgery is an option?

Look beyond the stage number

Stage III generally means cancer has spread locally or to regional lymph nodes without distant metastases. It does not describe one uniform amount of disease. The exact location and extent of nodal involvement can change the balance between an operation and definitive chemoradiation.

Ask your team to show the primary tumor and involved nodes on the scans. If a node determines the treatment route, ask whether tissue confirmation is needed. A written TNM description and the staging edition help another specialist understand the assessment precisely.

Sources and references: [1]

What a resectability decision includes

Resectability asks whether the cancer can be removed adequately with an acceptable surgical approach. Operability also considers whether you can tolerate the required operation. These questions are related but distinct: a technically removable tumor may still require too much physiological risk.

A thoracic surgeon, medical oncologist and radiation oncologist may each see a different part of the problem. Ask whether the plan has had multidisciplinary review, particularly if surgery is being offered after initial systemic treatment or if different hospitals have given conflicting recommendations.

Sources and references: [1]

When surgery forms part of treatment

For selected resectable stage III cancers, systemic treatment may be given before surgery, with treatment afterward determined by the chosen regimen and final findings. Chemotherapy and immunotherapy combinations are used in suitable patients; molecular features can affect that choice.

Before starting, clarify how the team will judge readiness for surgery and what would happen if the tumor progresses or the operation is no longer appropriate. This is also the time to ask whether the expected resection is a lobectomy or a larger operation, and what recovery is likely to involve.

Sources and references: [1]

When treatment proceeds without an operation

For fit patients with unresectable stage III NSCLC, concurrent chemotherapy and chest radiation are a common approach with curative intent. Giving them together can be demanding. Swallowing discomfort, fatigue and inflammation in the lungs may affect treatment tolerance.

If concurrent treatment is unsuitable, sequential chemotherapy and radiation or a less intensive approach may be considered. Ask which health factor changes the recommendation. The aim is to choose a course you can complete, while keeping the cancer-control goal clear.

Sources and references: [1]

The next treatment depends on more than the scan response

After chemoradiation, patients without progression may be considered for additional treatment. Durvalumab is an established option in appropriate settings. EGFR exon 19 deletion or L858R disease requires a specific discussion about osimertinib after chemoradiation, reflecting a different molecular pathway.

Ask when EGFR and other relevant tests will be available and how the result affects this decision. Lung inflammation after radiation also matters when considering further treatment. The plan should explain the drug, duration, monitoring and the reason it suits your cancer.

Sources and references: [1] [2]

Compare radiation plans using the organs at risk

Tumor coverage has to be balanced against exposure to healthy lungs, heart, esophagus and spinal cord. Modern planning can help manage this trade-off. If another radiation technique is proposed, ask what it changes on your own dose plan.

Previous chest radiation, interstitial lung disease and reduced lung function deserve attention before treatment. A technology name alone is a poor basis for choosing a center. More useful questions are whether the target can be covered safely, how breathing movement is handled and how symptoms will be reviewed during the course.

Sources and references: [1]

When another opinion can resolve a real uncertainty

A second review is especially useful when the team disagrees about resectability, the proposed operation is extensive, or molecular results were missing when the plan was made. Ask the receiving team to answer the disputed question directly.

Gather the actual CT and PET images, brain imaging if performed, pathology and nodal sampling reports, pulmonary tests and treatment dates. Keep your current oncologist informed about the review schedule. If symptoms are worsening, immediate assessment should continue while the records are being assembled.

Sources and references: [1]

Organizing a stage III review in Shanghai

EastMedGo can help you prepare an appointment inquiry focused on surgery versus definitive chemoradiation, or on treatment after chemoradiation. The Shanghai Chest Hospital profile and multidisciplinary-review information are starting points for discussing the required specialties.

Tell us which part of the plan is uncertain and when the next treatment is due. We can help clarify the receiving hospital's record requirements, visit sequence and coordination charges. That makes the inquiry useful before you commit to a longer stay for treatment.

Common questions